NCT06553872 Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL Status RECRUITING Phase PHASE2
NCT06533579 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Status RECRUITING Phase PHASE1/PHASE2
NCT06522386 GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06504199 Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06482684 CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT06363994 A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL Status RECRUITING Phase PHASE3
NCT06357676 Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial Status RECRUITING Phase PHASE1/PHASE2
NCT06341556 A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT06340737 AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Status RECRUITING Phase PHASE1
NCT06324994 Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. Status NOT_YET_RECRUITING Phase PHASE2
NCT06300528 Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06263491 Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients Status RECRUITING Phase PHASE2
NCT06255704 A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients Status NOT_YET_RECRUITING Phase PHASE2
NCT06252675 Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT06208735 CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies Status RECRUITING Phase PHASE1
NCT06192888 A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06151730 Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study Status RECRUITING Phase N/A